• menu
    Market Place Market Place
    Sourcing Support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Evonik
    |
    Weekly News Recap #Phispers
    Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug

    Chiesi, Arbor in US$ 2 bn gene therapy deal; Lilly to invest over US$ 1 bn in India; FDA okays Boehringer’s rare lung disease drug

    In news this week, Italy’s Chiesi Group announced a deal worth up to US$ 2 billion with US-based Arbor Biotechnologies to...

    Impressions : 2947

    Trump, Pfizer seal deal to offer drug discounts; FDA approves Eli Lilly’s oral breast cancer pill

    Trump, Pfizer seal deal to offer drug discounts; FDA approves Eli Lilly’s oral breast cancer pill

    This week, US President Donald Trump announced a deal with Pfizer to sell medicines through a new federal website, TrumpRx.go...

    Impressions : 564

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    In this week’s Phispers, Pfizer announced the acquisition of New York-based biotech Metsera for up to US$ 7.3 billion, ma...

    Impressions : 1254

    Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US

    Novartis inks US$ 5.7 bn licensing deal with Monte Rosa for immune-related diseases; GSK, Lilly pledge more investments in US

    In this week’s news, drugmakers continued to invest heavily in the US in order to avoid tariffs. GSK said it will invest ...

    Impressions : 910

    Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs

    Advent to sell generic unit to PE firm GTCR for US$ 4.8 billion; Novo shapes up for obesity race by cutting 9,000 jobs

    In this week’s news, Advent International has agreed to sell the Czech generic drugmaker Zentiva to private equity firm G...

    Impressions : 694

    Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight

    Novartis inks US$ 5.2 bn cardiology deal with China’s Argo, US$ 2 bn deal with Arrowhead; FDA okays first GLP-1 generic for weight

    Novartis signed two deals this week — a US$ 5.2 billion cardiology deal with China’s Argo Biopharmaceuticals, and a...

    Impressions : 756

    White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema

    White House sacks CDC director; FDA okays Ionis’ Dawnzera, first RNA-based preventive for hereditary angioedema

    The Trump administration has fired US Centers for Disease Control and Prevention (CDC) Director Susan Monarez, post a policy di...

    Impressions : 1037

    FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity

    FDA grants accelerated approval to Wegovy for treating MASH; Lilly, Superluminal ink US$1.3 bn AI deal to treat obesity

    This week’s Phispers brings you updates on key drug approvals. The US Food and Drug Administration (FDA) has granted acce...

    Impressions : 1385

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...

    Impressions : 1497

    Trump says pharma tariffs may touch 250% in 18 months; FDA okays Jazz Pharma’s rare brain tumor drug

    Trump says pharma tariffs may touch 250% in 18 months; FDA okays Jazz Pharma’s rare brain tumor drug

    The US Food and Drug Administration (FDA) has granted an accelerated approval to Jazz Pharmaceuticals’ Modeyso, a drug th...

    Impressions : 831

    Consortium makes ~US$ 3 bn offer to buy Bavarian Nordic; FDA approves PTC’s rare genetic disorder drug

    Consortium makes ~US$ 3 bn offer to buy Bavarian Nordic; FDA approves PTC’s rare genetic disorder drug

    The US Food and Drug Administration (FDA) has approved PTC Therapeutics’ oral drug to treat a rare genetic disorder known...

    Impressions : 945

    Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year

    Astra to invest US$ 50 bn in US to avoid tariffs; Dr. Reddy’s to launch generic Wegovy in 87 countries next year

    AstraZeneca and Biogen are the latest drugmakers to announce investments in the US to avoid import tariffs. AstraZeneca is in...

    Impressions : 1231

    Sarepta lays off 500 employees post second death in Elevidys trial; FDA chief proposes lowering PDUFA fee

    Sarepta lays off 500 employees post second death in Elevidys trial; FDA chief proposes lowering PDUFA fee

    This week’s Phispers brings you updates on cell and gene therapies (CGTs). After the death of a second teenaged boy last ...

    Impressions : 4270

    Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

    Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

    The world of pharmaceuticals continued to witness large deals. Merck announced a US$ 10 billion acquisition of Verona Pharma, g...

    Impressions : 683

    AbbVie doubles down on immunology with US$ 2.1 bn Capstan buyout; India’s Torrent buys controlling stake in JB Chem

    AbbVie doubles down on immunology with US$ 2.1 bn Capstan buyout; India’s Torrent buys controlling stake in JB Chem

    This week in Phispers, AbbVie struck a deal worth up to US$ 2.1 billion to acquire Capstan Therapeutics and its innovative in v...

    Impressions : 715

    Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer

    Royalty Pharma inks US$ 2 bn cancer drug deal with Revolution; Astra-Daiichi’s Datroway wins US approval for lung cancer

    In news this week, Royalty Pharma committed up to US$ 2 billion to Revolution Medicines for their promising pancreatic and lung...

    Impressions : 3040

    Lilly acquires gene-editing firm Verve for US$ 1.3 bn, BioNTech buys CureVac; Astra signs US$ 5.3 bn AI deal with China’s CSPC

    Lilly acquires gene-editing firm Verve for US$ 1.3 bn, BioNTech buys CureVac; Astra signs US$ 5.3 bn AI deal with China’s CSPC

    This week’s Phispers comes with news on several M&A deals. Eli Lilly made headlines with its US$ 1.3 billion acquisition ...

    Impressions : 692

    RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials

    RFK Jr fires all 17 members of CDC’s vaccine committee; Merck’s oral cholesterol drug meets goals in late-stage trials

    This week, US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. dismissed all 17 members of the US Centers for D...

    Impressions : 1130

    BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn

    BMS partners BioNTech in US$ 11 bn cancer drug deal; Sanofi to acquire Blueprint Medicines for US$ 9.5 bn

    The pharmaceutical sector saw several significant deals with major players expanding their portfolios. Bristol Myers Squibb (BM...

    Impressions : 625

    Lilly expands pain pipeline via US$ 1 bn SiteOne buyout; US cancels funding for Moderna’s bird flu vaccine

    Lilly expands pain pipeline via US$ 1 bn SiteOne buyout; US cancels funding for Moderna’s bird flu vaccine

    In news this week, Eli Lilly has placed a billion-dollar bet on non-opioid pain management by acquiring SiteOne Therapeutics fo...

    Impressions : 716

    Pfizer inks US$ 6 bn oncology deal with China’s 3SBio; BioNTech to invest US$ 1.3 bn in UK for new R&D, AI centers

    Pfizer inks US$ 6 bn oncology deal with China’s 3SBio; BioNTech to invest US$ 1.3 bn in UK for new R&D, AI centers

    In news this week, Pfizer announced a US$ 6 billion licensing agreement with China’s 3SBio, securing global rights to a p...

    Impressions : 747

    Trump signs ‘most favored nation’ executive order to slash drug costs; Sanofi, Takeda pledge mega investments in US

    Trump signs ‘most favored nation’ executive order to slash drug costs; Sanofi, Takeda pledge mega investments in US

    The US President Donald Trump’s dramatic intervention in pharmaceutical pricing took centerstage as the White House unvei...

    Impressions : 817

    BMS to invest US$ 40 bn to boost US manufacturing, R&D; 19 states sue Trump admin for gutting health agencies

    BMS to invest US$ 40 bn to boost US manufacturing, R&D; 19 states sue Trump admin for gutting health agencies

    US President Donald Trump’s tariff threats appear to be working, as Bristol Myers Squibb became the latest drugmaker to a...

    Impressions : 1758

    AbbVie, Amgen, Thermo Fisher to invest in US manufacturing to avoid tariffs; Merck KGaA acquires SpringWorks for US$ 3.9 bn

    AbbVie, Amgen, Thermo Fisher to invest in US manufacturing to avoid tariffs; Merck KGaA acquires SpringWorks for US$ 3.9 bn

    Ever since US President Donald Trump has talked about a “major tariff” on drug imports coming “very shortly&r...

    Impressions : 972

    Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm

    Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm

    After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...

    Impressions : 1166

    Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill

    Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill

    After Eli Lilly and Johnson & Johnson, Novartis has become the latest big pharma to announce mega investments in the US. The ...

    Impressions : 1010

    Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology

    Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology

    In this week’s news, US President Donald Trump has said “major” pharmaceutical import tariffs are coming soon...

    Impressions : 1176

    CBER director forced out in FDA gutting; Sanofi, Alnylam’s RNAi therapy Qfitlia wins US approval for hemophilia A, B

    CBER director forced out in FDA gutting; Sanofi, Alnylam’s RNAi therapy Qfitlia wins US approval for hemophilia A, B

    The pharma industry saw its most tumultuous week in the recent past with the US Food and Drug Administration (FDA) facing an un...

    Impressions : 1065

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.